⇨ Yard­ley, PA-based Opti­Nose is join­ing the grow­ing line for Nas­daq, fil­ing for a $100 mil­lion IPO, ac­cord­ing to the S-1. The fil­ing came right on the heels of an OK for XHANCE — pre­vi­ous­ly re­ferred to by the de­vel­op­ment name OPN-375 — for the treat­ment of nasal polyps.

⇨ GSK got some good news to­day, win­ning FDA ap­proval of the first three-in-one once-dai­ly ther­a­py for COPD. The move comes af­ter the EMA en­dorsed the in­haler last week.

⇨ Af­ter near­ly a decade spent col­lab­o­rat­ing with Cel­gene, Ac­celeron $XL­RN says it has gained rights to de­vel­op so­tater­cept for pul­monary ar­te­r­i­al hy­per­ten­sion, with plans to launch a Phase II study dur­ing the first half of next year.

⇨ The mi­cro­cap biotech Ju­niper Phar­ma­ceu­ti­cals $JNP is re­fo­cus­ing and re­or­ga­niz­ing. The plan is to slash the staff ros­ter by 8% and con­cen­trate on “the core busi­ness­es of Crinone prog­es­terone gel and Ju­niper Phar­ma Ser­vices” at the Boston-based women’s health­care com­pa­ny.

⇨ Nabri­va Ther­a­peu­tics $NBRV is fol­low­ing up on a pos­i­tive Phase III study for its an­tibi­ot­ic with an $80 mil­lion stock of­fer­ing.

Eli Lilly has succeeded in its attempt to get the first non-covalent version of Bruton’s tyrosine kinase, or BTK, inhibitors to market, pushing it past rival Merck.

The FDA gave an accelerated nod to Lilly’s daily oral med, to be sold as Jaypirca, for patients with relapsed or refractory mantle cell lymphoma.

The agency’s green light, disclosed by the Indianapolis Big Pharma on Friday afternoon, catapults Lilly into a field dominated by covalent BTK inhibitors, which includes AbbVie and Johnson & Johnson’s Imbruvica, AstraZeneca’s Calquence and BeiGene’s Brukinsa.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in favor of “harmonizing” Covid vaccine compositions, meaning all current vaccine recipients would receive a bivalent vaccine, regardless of whether they’ve gotten their primary series.

The vote marks an effort to clear up confusion around varying formulations and dosing schedules for current primary series and booster vaccines, as well as “get closer to the strains that are circulating,” according to committee member Paul Offit, professor of pediatrics at the Children’s Hospital of Philadelphia.

The CDMO arm of one of South Korea’s largest conglomerates has posted its year-end results and plans for 2023, which include new construction.

Samsung Biologics netted north of KRW 3 trillion ($2.4 billion) in 2022 revenue and an operating profit of KRW 983.6 billion ($799 million), which the company touted on Friday as “record-high earnings.” The revenue boost was 55% compared to 2021.

Novartis’ sickle cell drug, approved in 2019 and branded as Adakveo, has failed an ongoing Phase III, according to preliminary results.

The Swiss pharma giant unveiled early data from the ongoing STAND Phase III study on Friday, saying that crizanlizumab showed no statistically significant difference between the drug at two different dose levels compared to placebo in annualized rates of vaso-occlusive crises that lead to a healthcare visit over the first year since being randomized into the trial.